Vascular and Transplant Specialists, Virginia Beach, VA 23452, USA.
Semin Vasc Surg. 2011 Jun;24(2):108-12. doi: 10.1053/j.semvascsurg.2011.05.006.
Chronic hemodialysis via a tunneled dialysis catheter (TDC) is associated with a high incidence of infectious complications and increased mortality and, therefore, should only be considered when all other options for vascular access are exhausted. The Hemoaccess Reliable Outflow (HeRO) Vascular Access Device (Hemosphere, Inc., Minneapolis, MN) is an alternative to the TDC. Early results suggests that the infectious complications are significantly less for the HeRO device when compared to the TDC, and the secondary patency for the device approximates that for prosthetic accesses. The device can be successfully placed in >90% of catheter-dependent patients. Chronic hemodialysis via the HeRO Device is preferable to TDC use.
经隧道透析导管（TDC）进行慢性血液透析与较高的感染并发症发生率和死亡率相关，因此，只有在所有其他血管通路选择都已用尽的情况下才应考虑该方法。Hemoaccess Reliable Outflow（HeRO）血管通路装置（Hemosphere，Inc.，明尼苏达州明尼阿波利斯）是 TDC 的替代方法。早期结果表明，与 TDC 相比，HeRO 装置的感染并发症明显更少，并且该装置的继发性通畅率接近人造血管通路。该装置可成功放置在＞90%的导管依赖患者中。与 TDC 相比，使用 HeRO 装置进行慢性血液透析更优。
